Japanese pharmaceutical company headquartered in Nihonbashi, Chuo ward, Tokyo, founded in 1925, listed in Tokyo and majority owned by Roche since their strategic alliance in 2002 while remaining independently managed. Researches, develops, makes and sells prescription medicines with a strong antibody engineering platform, producing tocilizumab for rheumatoid arthritis and related diseases, the bispecific antibody emicizumab for haemophilia A and the ALK inhibitor alectinib for lung cancer, and runs research centres at Kamakura and Ukima and plants at Utsunomiya and Fujieda.
No hay comentarios disponibles.
Deja tu valoración & comentario